EXAMINE THIS REPORT ON HEMGENIX

Amount of eligible people: CDEC reviewed the uncertainty in the amount of people with moderately intense to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some patients who're categorised as getting delicate or reasonable sickness might have a significant bleeding phenotyp